Filing Analysis
Officer Departure
Filed Apr 10, 2026
MEDIUM
Kalaris Therapeutics announced the resignation of CFO Matthew Gall, effective April 14, 2026. Brett Hagen, the company's current Chief Accounting Officer, will assume the role of Principal Financial Officer.
Red Flags
- Short notice period (6 days) between the resignation notification and the effective separation date.
- The company is a micro-cap biotech where CFO turnover can often precede capital raises or strategic shifts.
Key Facts
- Matthew Gall notified the company of his resignation as CFO on April 8, 2026.
- The resignation is effective April 14, 2026, representing a short notice period of six days.
- Brett Hagen, 53, has been appointed as the Principal Financial Officer effective April 14, 2026.
- Hagen has served as the company's Chief Accounting Officer since January 2019.
- No changes were made to Hagen's compensatory plans in connection with the appointment.
Regulation FD Disclosure
Filed Mar 17, 2026
LOW
Kalaris Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025. The results were released via a press release furnished as an exhibit to the filing.
Key Facts
- The filing was made on March 17, 2026, reporting on the fiscal year ended December 31, 2025.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results is included as Exhibit 99.1.
- The company is listed on The Nasdaq Global Market under the symbol KLRS.
Regulation FD Disclosure
Filed Mar 09, 2026
LOW
Kalaris Therapeutics furnished an updated corporate presentation for the Leerink Partners Global Healthcare Conference on March 9, 2026. The presentation provides updated clinical timelines for its lead candidate TH103 and revised cash runway guidance.
Red Flags
- Forward-looking statements highlight risks related to the inability to obtain sufficient additional capital to advance product candidates
Key Facts
- Updated timelines for reporting data from the Phase 1b/2 multi-ascending dose clinical trial of TH103
- Updated timelines for initiating Phase 3 clinical development of TH103
- Provision of updated cash runway guidance
- Presentation scheduled for use at the Leerink Partners Global Healthcare Conference
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.